2-[2-Fluoro-4-(trifluoromethyl)phenyl]ethanol | 886761-78-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-[2-Fluoro-4-(trifluoromethyl)phenyl]ethanol
• CAS: 886761-78-0
• 化学式: C₉H₈F₄O
• mdl: MFCD06660357
• 分子量: 208.15
• InChiKey: ZZPFABXJRPFKOI-UHFFFAOYSA-N

物化性质

• 沸点：
  212.1±35.0 °C(Predicted)
• 密度：
  1.321±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  14
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.333
• 拓扑面积：
  20.2
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS PYRAZOLYLE PYRIMIDINONE UTILISÉS EN TANT QU'INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2016154081A1

  公开（公告）日：2016-09-29

  The present invention is directed to pyrimidine carboxamide compounds of formula I which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及式I的嘧啶甲酰胺化合物，该化合物作为治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的治疗剂是有用的。本发明还涉及使用这些化合物来治疗神经和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能减退或基底神经节功能障碍相关的疾病。
• [EN] HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS<br/>[FR] COMPOSÉS D'HÉTÉROARYL-PYRIMIDINONE EN TANT QU'INHIBITEURS DE PDE2
  申请人：MERCK SHARP & DOHME

  公开号：WO2016179059A1

  公开（公告）日：2016-11-10

  The present invention is directed to substituted pyrimidinone compounds of formula (I) which are useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 2 (PDE2). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis, Parkinson's disease, Parkinson's disease dementia (PDD), or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.

  本发明涉及一种具有以下式（I）的取代嘧啶酮化合物，其可用作治疗与磷酸二酯酶2（PDE2）相关的中枢神经系统疾病的治疗剂。本发明还涉及利用这类化合物治疗神经系统和精神疾病，如精神分裂症、精神病、帕金森病、帕金森病痴呆（PDD）或亨廷顿病，以及与纹状体功能不足或基底神经节功能障碍相关的疾病。
• PYRAZOLYL PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3285581A1

  公开（公告）日：2018-02-28
• HETEROARYL-PYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3291817A1

  公开（公告）日：2018-03-14
• DIHYDROPYRAZOLOPYRIMIDINONE COMPOUNDS AS PDE2 INHIBITORS
  申请人：Merck Sharp & Dohme Corp.

  公开号：EP3302486A1

  公开（公告）日：2018-04-11